Lynn L Silver

List of Publications by Year
in descending order

43 papers	9,265 citations	147786 31 h-index	289230 40 g-index
47 all docs	47 docs citations	47 times ranked	11346 citing authors

#	Article	IF	Citations
1	Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0199121.	3.2	103
2	Perspective on Antibacterial Lead Identification Challenges and the Role of Hypothesis-Driven Strategies. SLAS Discovery, 2019, 24, 440-456.	2.7	7
3	Analysis of the clinical antibacterial and antituberculosis pipeline. Lancet Infectious Diseases, The, 2019, 19, e40-e50.	9.1	161
4	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infectious Diseases, The, 2018, 18, 318-327.	9.1	3,672
5	Fosfomycin: Mechanism and Resistance. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a025262.	6.2	205
6	What is an â€œidealâ€•antibiotic? Discovery challenges and path forward. Biochemical Pharmacology, 2017, 133, 63-73.	4.4	141
7	The Antibiotic Future. Topics in Medicinal Chemistry, 2017, , 31-67.	0.8	11
8	Appropriate Targets for Antibacterial Drugs. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a030239.	6.2	51
9	A Gestalt approach to Gram-negative entry. Bioorganic and Medicinal Chemistry, 2016, 24, 6379-6389.	3.0	140
10	Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1. Antimicrobial Agents and Chemotherapy, 2016, 60, 936-945.	3.2	22
11	Natural products as a source of drug leads to overcome drug resistance. Future Microbiology, 2015, 10, 1711-1718.	2.0	32
12	New Targets for Antibacterial Compounds. , 2015, , 249-274.		0
13	70th Anniversary Collection for the Microbiology Society: Journal of Medical Microbiology. Journal of Medical Microbiology, 2015, 64, 1457-1461.	1.8	0
14	Antibacterials for any target. Nature Biotechnology, 2014, 32, 1102-1104.	17.5	9
15	Multitarget ligands in antibacterial research: progress and opportunities. Expert Opinion on Drug Discovery, 2013, 8, 143-156.	5.0	54
16	Viable screening targets related to the bacterial cell wall. Annals of the New York Academy of Sciences, 2013, 1277, 29-53.	3.8	50
17	Rational Approaches to Antibacterial Discovery: Pre-Genomic Directed and Phenotypic Screening. , 2012, , 33-75.		21
18	Challenges of Antibacterial Discovery. Clinical Microbiology Reviews, 2011, 24, 71-109.	13.6	1,106

#	Article	IF	Citations
19	A persistent problem. Journal of Medical Microbiology, 2011, 60, 267-268.	1.8	2
20	Are natural products still the best source for antibacterial discovery? The bacterial entry factor. Expert Opinion on Drug Discovery, 2008, 3, 487-500.	5.0	72
21	Novel broad spectrum Î²-lactamase inhibitors. Expert Opinion on Therapeutic Patents, 2007, 17, 1175-1181.	5.0	8
22	Multi-targeting by monotherapeutic antibacterials. Nature Reviews Drug Discovery, 2007, 6, 41-55.	46.4	248
23	Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature, 2006, 441, 358-361.	27.8	785
24	Does the cell wall of bacteria remain a viable source of targets for novel antibiotics?. Biochemical Pharmacology, 2006, 71, 996-1005.	4.4	98
25	Discovery of FabH/FabF Inhibitors from Natural Products. Antimicrobial Agents and Chemotherapy, 2006, 50, 519-526.	3.2	192
26	Determination of Selectivity and Efficacy of Fatty Acid Synthesis Inhibitors. Journal of Biological Chemistry, 2005, 280, 1669-1677.	3.4	105
27	A retrospective on the failures and successes of antibacterial drug discovery. IDrugs: the Investigational Drugs Journal, 2005, 8, 651-5.	0.7	5
28	Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A Î²-Lactamase, KPC-3, in a New York Medical Center. Antimicrobial Agents and Chemotherapy, 2004, 48, 4793-4799.	3.2	402
29	Novel Pyrazolo[3,4-d]pyrimidine-Based Inhibitors ofStaphlococcus aureusDNA Polymerase III:Â Design, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 2003, 46, 1824-1830.	6.4	57
30	Novel illudins from Coprinopsis episcopalis (syn. Coprinus episcopalis), and the distribution of illudin-like compounds among filamentous fungi. Mycological Research, 2003, 107, 1201-1209.	2.5	39
31	Novel inhibitors of bacterial cell wall synthesis. Current Opinion in Microbiology, 2003, 6, 431-438.	5.1	100
32	Design and synthesis of novel antibacterial agents with inhibitory activity against DNA polymerase III. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2185-2188.	2.2	20
33	Direct interaction of a vancomycin derivative with bacterial enzymes involved in cell wall biosynthesis. Chemistry and Biology, 2001, 8, 1095-1106.	6.0	38
34	The Role of Hydrophobic Substituents in the Biological Activityof Glycopeptide Antibiotics. Journal of the American Chemical Society, 2000, 122, 12608-12609.	13.7	106
35	In Vitro Activities of the Potent, Broad-Spectrum Carbapenem MK-0826 (L-749,345) against Broad-Spectrum Î²-Lactamase-and Extended-Spectrum Î²-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli Clinical Isolates. Antimicrobial Agents and Chemotherapy, 1999, 43, 1170-1176.	3.2	73
36	Carbohydroxamido-oxazolidines: antibacterial agents that target lipid A biosynthesis. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 313-318.	2.2	46

#	Article	IF	Citations
37	Inhibition of IMP-1 metallo-ÃŽÂ²-lactamase and sensitization of IMP-1-producing bacteria by thioester derivatives. FEMS Microbiology Letters, 1999, 179, 289-296.	1.8	37
38	Vancomycin Derivatives That Inhibit Peptidoglycan Biosynthesis Without Binding D-Ala-D-Ala. Science, 1999, 284, 507-511.	12.6	337
39	Reduced Immunotoxicity and Preservation of Antibacterial Activity in a Releasable Side-Chain Carbapenem Antibiotic. Science, 1999, 283, 703-706.	12.6	33
40	Antibacterial Agents That Inhibit Lipid A Biosynthesis. Science, 1996, 274, 980-982.	12.6	394
41	The envA Permeability/Cell Division Gene of Escherichia coli Encodes the Second Enzyme of Lipid A Biosynthesis. Journal of Biological Chemistry, 1995, 270, 30384-30391.	3.4	176
42	Screening of natural products for antimicrobial agents. European Journal of Clinical Microbiology and Infectious Diseases, 1990, 9, 455-461.	2.9	87
43	The construction and replication properties of hybrid plasmids composed of the r-determinant of R100.1 and the plasmids pCRI or pSC201. Molecular Genetics and Genomics, 1979, 168, 337-340.	2.4	12